1579 results about "Antibody detection" patented technology

The present invention relates to anti-heteronucleic acid antibodies and their uses for detection of RNA-DNA duplexes on arrays. The invention provides a method for detection of total cellular RNA hybridization on microarrays, thus obviating the need for isolation of the poly(A)+ fraction.

The invention provides a detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), and relates to the technical field of biology. According to the detection kit of IgM/IgG antibodies of novel coronavirus (SARS-CoV-2), the IgM/IgG antibodies of novel coronavirus (SARS-CoV-2) are detected through adoption of a colloidal gold capture method, a colloidal gold indirect method and a colloidal gold double antigen sandwich method, wherein adopted antigens are highly active recombinant antigens which are obtained through fusion expression of N protein fragments and S protein dominant epitope fragments, and colloidal gold is labeled indirectly, so that steric hindrance is reduced, and the activity, reaction consistency and accuracy of the antigens are increased. Since a sample pad is pretreated, the interference of complex components in a blood sample to a reaction can be reduced greatly, the detection kit has no requirements for instruments during detection, simple and flexible operation, direct and manual interpretation of results and a short test time, the results can be interpreted in only 15 minutes, and the test results are accurate.

Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described.

The present invention provides the following: a method for efficiently producing a reagent for detecting an antibody that specifically binds with an insoluble antigen protein present in a liquid sample; a reagent for antibody detection produced by the production method; and a use of the antibody. In a step for solubilizing an antigen protein, it is possible to efficiently solubilize and recover the antigen protein by using a cationizing agent; therefore, when compared to conventional methods, it is possible to efficiently produce a reagent for detecting an antibody that has bound to multiple antigen protein molecules in a carrier.

Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.

The invention relates to biology applied technology field, especially relates to a immune chromatography assay for quickly detecting the human immunologic deficiency disease (HIV) antibody and antigen. The assay comprises two independent test papers A and B and plastic case C for storing the test paper, wherein the test paper A is used for detecting the HIV antibody and the test paper B is used for detecting the HIV p24 antigen. The test paper A and test paper B are parallely encased in the plastic case to constitute the assay. On detecting, the detected sample is added on the sample pad of the test paler and the immunoreaction result is directly observed to perform detection. The assay is used for screening or clinical diagnosis of the HIV infection and at the same time the HIV antigen and antibody are detected, the simpler antibody detection can effectively reduce the window phase for detecting the HIV, with features of quick reaction, easy operation, economy and practicality, suitable for insitu detecting.

The presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample can serve as an important clinical or other analytical or diagnostic tool. ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies and hybridomas producing them, are developed to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.

This invention related generally to methods of detecting and quantifying biomarkers of oxidative stress in proteins. The biomarker may be any amino acid that has undergone oxidation (or other modification, e.g. chloro-tyrosine, dityrosine). Emphasis is given herein on oxidized sulfur- or selenium-containing amino acids (SSAA). The biomarker of oxidative stress in proteins may be detected with an antibody that binds to oxidized amino acids, specifically oxidized sulfur- or selenium-containing amino acids. The antibody may be monoclonal or polyclonal. The presence of biomarker or amount of biomarker present in a sample may be used to aid in assessing the efficacy of environmental, nutritional and therapeutic interventions, among other uses.

The invention provides an antibody detection double-antigen sandwich method using nanoparticles. A nanoparticle label and a label between the labeled antigens implement an indirect labeling by combining the label on an antigen and a ligand which is labeled on the nanoparticle label and can specifically recognize the label, wherein the labeled antigen is a gene engineering recombined antigen. Withthe indirect labeling manner, the sensitivity and the specificity of the method can be remarkably improved.

A method for simply and conveniently detecting acetyltransferase and deacetylase activities of proteins by executing an acetylation reaction of a peptide substrate with an acetyltransferase, or a deacetylation reaction of an acetylated peptide substrate with a deacetylase, and after the completion of these reactions, detecting the acetyl group bound to the peptide substrate by using an anti-acetylated peptide antibody. This system for detecting acetyltransferase and deacetylase activities using the anti-acetylated peptide antibody enables screening inhibitors or enhancers of acetyltransferase and deacetylase. A system for screening deacetylase inhibitors or acetyltransferase enhancers using cultured cells is also provided.

A bridging assay that utilizes a multivalent MHC binding molecule to enumerate the number of antigen-specific CTLs in a particular sample and also determines the functional capability of the CTL population in the sample is provided. In one embodiment, the assay is used to measure the effector function of any tetramer-positive CTL using a single non-MHC-containing target cell line that is adapted to form an antibody bridge with the tetramer. Furthermore, effector function and enumeration can be measured by flow cytometry, and additional markers residing on either effector or target cell populations may be detected using antibodies coupled with other fluorochromes. The tetramer bridging assay will allow investigators to easily determine the lytic capacity and antigenic specificity of CTLs using a commercially available reagent in a non-radioactive assay.

The invention discloses a fluorescent microsphere immunochromatographic testing card for testing five indexes of hepatitis b and a method for preparing the same. The testing card comprises a hepatitis b surface antigen test paper strip, a hepatitis b e surface antigen test paper strip, a hepatitis b surface antibody test paper strip, a hepatitis b e surface antibody test paper strip, and a hepatitis b core antibody test paper strip. Each test paper strip is formed by overlapping and bonding filter paper, a sample pad, a glass fiber film spray-coated with fluorescent microspheres, a cellulose nitrate film and water absorption paper on a bottom plate by glue in sequence, wherein the cellulose nitrate film is coated with antigens serving as a testing area and anti-rabbit antibodies serving as a quality control area; and during a test, after emitted fluorescent light passes a filter, the emitted spectrum is collected, accumulated and multiplied by the CCD scanning technology and then converted into a numerical signal, the numerical signal is multiplied by a correction factor, and the strength of the corrected fluorescent light is substituted in a standard curve of a fluorescence analyzer, so that the concentrations of the five indexes of hepatitis b of the sample can be automatically worked out. The test of hepatitis b viruses by the testing card has the characteristics of specificity, sensitivity, simpleness and accuracy.

The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized LK26 specific antibodies. Additionally, the invention provides methods of treating cancer using LK26 specific antibodies.

The invention is directed to recombinant antibodies which bind to Sclerotinia sclerotiorum antigens and comprise a single chain variable fragment (scFv). The antigen may be selected from SSPG1d or a portion thereof, aspartyl protease or a portion thereof, or whole Sclerotinia sclerotiorum mycelium. The invention also provides an antibody linked to an anti-fungal polypeptide. The invention extends to nucleic acid sequences encoding the antibodies, and expression vectors comprising the nucleic acid sequences. The invention is also directed to transgenic plants, seeds, tissues or cells transformed with the expression vectors. Methods for producing a transgenic plant that is resistant to Sclerotinia sclerotiorum, and for detecting Sclerotinia sclerotiorum in a biological sample utilizing an antibody which binds to Sclerotinia sclerotiorum antigen, and immunoassay kit for same are also provided.

The present invention relates to novel arginine analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or free thiol (—SH) group, thereby providing a convenient linkage chemistry for coupling to a suitable group on a target such as a protein, polypeptide, detectable label or solid phase, and at a site distal to the guanidino group. Arginine analog conjugates are useful for generating antibodies that can bind specifically with dimethylarginine, which can be detected using such antibodies in immunoassays.